| | | | nm |
Anti-GD2/microRNA-34a- -silica NPs | GD2 | Organic-inorganic | MicroRNA-34a | 74 | In vitro/in vivo | Tivnan et al. (2012) |
HSYWLRS Peptide/DOX-liposomes | Neuropilin-1 | Lipid | DOX | 130 | In vitro/in vivo | Loi et al. (2013), Cossu et al. (2015) |
Anti-GD2/iron oxide NPs | GD2 | Metallic | — | 99 | In vitro/in vivo | Xu et al. (2014), Baiu et al. (2015) |
AntiGD2/ALK siRNA liposomes | GD2 | Lipid | ALK siRNA | 135–165 | In vitro/in vivo | Di Paolo et al. (2015) |
NGR peptide/bortezomib liposomes | aminopeptidase N | Lipid | Bortezomib | 165 | In vitro | Zuccari et al. (2015) |
Anti-GD2/gold NPs | GD2 | Metallic | — | 50 | In vitro | Jiao et al. (2016) |
RVG/PLGA-CaCO3 NPs | Nicotinic acetylcholine receptor | Polymeric | DOX | 200–220 | In vitro/in vivo | Lee et al. (2016), Jang et al. (2018) |
NACA/CDC20 siRNA-PTX- liposomes | Gaba receptor | Lipid | CDC20 siRNA + PTX | 130–150 | In vitro/in vivo | Bhunia et al. (2017) |
PGA/PTX NPs | Neural cell adhesion molecule | Polymeric | PTX | 9 | In vitro/in vivo | Markovsky et al. (2017) |
Anti-GD2/PLGA-PEG SN-38 NPs | GD2 | Polymeric | SN-38 | 272 | In vitro/in vivo | Monterrubio et al. (2017) |
Bevacizumab/SiO2 LDH DOX NPs | VEGF | Inorganic | DOX | 253 | In vitro/in vivo | Zhu et al. (2017) |
Dendritic PG/NTP-PTX-PEG NPs | Neural cell adhesion molecule | Polymeric | PTX | 70 | In vitro/in vivo | Vossen et al. (2018) |
Anti-GD2/YM155 liposomes | GD2 | Lipid | Sepantronium bromide | 170 | In vitro/in vivo | Gholizadeh et al. (2018) |